Fidelity is bullish on China. Goldman Sachs likes OZON. ARK’s Cathie Wood likes space exploration. But, seasonality does not bode well for markets in late January/February.
January returns weaken after options expiration Friday. Earnings season picks up next week, as a new US administration takes office. Expectations for a further rebound in stocks may already be baked in to consensus expectations.
Over the last few days, Treasury yields have risen significantly as Democratic wins in Georgia are likely to lead to more COVID relief spending. Besides looking at the the potential effects on the market, we address a few strategies to mitigate the risk of rising rates in a fixed income portfolio.
We review the US Democratic sweep as it applies to the sectors responding to more stimulus, regulation and COVID vaccines. Morgan Stanley and Citibank like airlines, including Southwest Airlines, GOL Linhas, and British Air Group.
Small cap stock picks continue to perform well, even as markets become more overbought.
A timely play in a company focused on autoimmune disease detection for diseases disproportionately affecting women.
Looking beyond 2021 economic strength, forecasts for 2022 are very positive. US cash levels remain elevated as markets hit all time highs. The USD weakens, while emerging markets strengthen and small caps come under pressure. FAAMG stocks take some of the Santa Claus Rally leadership.
U.S., estimated annual dialysis spending approximates $74B and the main market players have not changed for 30 years. A new medtech company is set to disrupt the market.
Certain market indicators are at levels of extreme bullishness. The run up in value stocks since the US elections has been shocking. Now is a good time to lighten up on bullish bets.
The month of January has quite a bullish reputation among investors, but post election years tend to be weaker then others.
A Dutch semi manufacturer may have secretly been awarded a contract to supply chips for space exploration. We see large call buyers expecting a bounce in the company’s shares.